Craig A. Erickson, MD
- Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience
- Board Certified
About
Biography
Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.
Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003.
MS: Indiana University School of Medicine, Indianapolis, IN, 2008.
Residency and Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2003-2008.
Certification: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008.
Interests
Fragile X syndrome; inpatient neurodevelopmental disorders acute crisis stabilization
Interests
Fragile X syndrome; autism spectrum disorders; neurodevelopmental disorders; molecular blood markers; quantitative measurement of pathophysiology in developmental disabilities; translational treatment development; psychiatric services for those with developmental disabilities and severe behavior
Publications
Specialization of the brain for language in children with Fragile X Syndrome: a functional Near Infrared Spectroscopy study. Journal of Neurodevelopmental Disorders. 2024; 16:69.
A near normal distribution of IQ in Fragile X Syndrome. Scientific Reports. 2024; 14:23058.
Developmental milestones and daily living skills in individuals with Angelman syndrome. Journal of Neurodevelopmental Disorders. 2024; 16:32.
Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome. Scientific Reports. 2024; 14:22982.
Innovative Approaches to Addressing Pediatric Mental Health. Pediatric Clinics of North America. 2024; 71:xvii-xix.
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines. 2024; 12:1430.
CNN Brain Label-Maker: Computer Vision Based ICA Rejection EEG based System Architecture. 2024; 37.
EEG Microstates as Markers for Cognitive Impairments in Fragile X Syndrome. Brain Topography: journal of functional neurophysiology. 2024; 37:432-446.
Neurodevelopmental Disorders Including Autism Spectrum Disorder and Intellectual Disability as a Risk Factor for Delayed Diagnosis of Catatonia. Journal of Developmental and Behavioral Pediatrics. 2024; 45:e137-e142.
Effects of AFQ056 on language learning in fragile X syndrome. The Journal of Clinical Investigation. 2024; 134:e171723.
From the Blog
Positive Clinical Trial Results for a New Fragile X Treatment
Craig A. Erickson, MD2/11/2025
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey